Strategic Planning for Bioanalytical Automation
Author Information
Author(s): Julie J. Tomlinson
Primary Institution: Glaxo Inc.
Hypothesis
How can bioanalytical automation be effectively managed and planned for growth?
Conclusion
The strategic plan for bioanalytical automation at Glaxo Inc. has successfully guided its growth and adaptation to challenges.
Supporting Evidence
- The strategic plan has been in effect for over a year and was reviewed with no changes necessary.
- The Bioanalytical Robotics group has successfully reduced the percentage of work contracted out from 70% to 30%.
- The robots currently analyze 20-30,000 samples per year, demonstrating their efficiency.
- Five robotic assays and two assays in automation development have been validated.
- The strategic plan outlines necessary resources and potential barriers for future growth.
Takeaway
This study shows how planning and teamwork can help a lab use robots to analyze a lot of samples quickly and accurately.
Methodology
The study involved analyzing the growth cycles and strategic planning processes of the Bioanalytical Robotics group at Glaxo Inc.
Potential Biases
Potential bias may arise from the focus on a single company's practices and the subjective nature of reported experiences.
Limitations
The study is limited to the experiences and outcomes of one specific group within a single company.
Participant Demographics
The study involved scientists and managers from the Bioanalytical Robotics group at Glaxo Inc.
Want to read the original?
Access the complete publication on the publisher's website